- Home
- WSC vs SLNO Comparison
WSC vs SLNO Comparison
Compare WSC & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WSC
- SLNO
- Stock Information
- Founded
- WSC 1944
- SLNO 1999
- Country
- WSC United States
- SLNO United States
- Employees
- WSC N/A
- SLNO N/A
- Industry
- WSC Misc Corporate Leasing Services
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- WSC Industrials
- SLNO Health Care
- Exchange
- WSC Nasdaq
- SLNO Nasdaq
- Market Cap
- WSC 2.8B
- SLNO 2.5B
- IPO Year
- WSC N/A
- SLNO 2014
- Fundamental
- Price
- WSC $17.60
- SLNO $45.72
- Analyst Decision
- WSC Buy
- SLNO Strong Buy
- Analyst Count
- WSC 8
- SLNO 10
- Target Price
- WSC $26.00
- SLNO $110.90
- AVG Volume (30 Days)
- WSC 4.3M
- SLNO 2.4M
- Earning Date
- WSC 11-06-2025
- SLNO 11-04-2025
- Dividend Yield
- WSC 1.58%
- SLNO N/A
- EPS Growth
- WSC 816.06
- SLNO N/A
- EPS
- WSC 1.20
- SLNO N/A
- Revenue
- WSC $2,317,990,000.00
- SLNO $98,675,000.00
- Revenue This Year
- WSC N/A
- SLNO N/A
- Revenue Next Year
- WSC $2.83
- SLNO $181.30
- P/E Ratio
- WSC $14.79
- SLNO N/A
- Revenue Growth
- WSC N/A
- SLNO N/A
- 52 Week Low
- WSC $14.91
- SLNO $41.50
- 52 Week High
- WSC $39.81
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- WSC 41.54
- SLNO 35.47
- Support Level
- WSC $14.91
- SLNO $44.20
- Resistance Level
- WSC $17.95
- SLNO $50.04
- Average True Range (ATR)
- WSC 1.12
- SLNO 3.25
- MACD
- WSC -0.07
- SLNO -0.32
- Stochastic Oscillator
- WSC 43.74
- SLNO 42.59
About WSC WillScot Mobile Mini Holdings Corp.
WillScot Holdings Corp designs, delivers, and services onsite, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company includes modular office complexes, mobile offices, portable storage containers, and others.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.